Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.
Mereo BioPharma Group plc (NASDAQ: MREO) is a United Kingdom-based biopharmaceutical company dedicated to developing innovative therapeutics for rare and specialty diseases. The company's primary focus is on acquiring and advancing mid-stage development programs from larger pharmaceutical firms, aiming to transform patient quality of life and improve human health. Mereo's strategy includes optimizing the commercial value of its programs through strategic partnerships or, for select opportunities, by commercializing products independently.
Mereo has a robust pipeline of late-stage clinical product candidates, particularly in rare disease areas. The company's flagship candidates include setrusumab for Osteogenesis Imperfecta (OI) and alvelestat for severe Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). Setrusumab, developed in partnership with Ultragenyx Pharmaceutical Inc., has shown promising results in reducing the annualized fracture rate by 67% in OI patients. The Phase 2/3 Orbit study continues to enroll patients, aiming for regulatory approvals from both the FDA and EMA.
Alvelestat, another key candidate, has demonstrated significant effects in clinical trials, including the ATALANTa study. The data supports its use for AATD-LD, and the company is aligning with both the FDA and EMA on Phase 3 study designs, targeting a broader patient population. Mereo is actively seeking partners for further development and commercialization of alvelestat.
Additionally, Mereo is advancing its oncology pipeline with candidates such as etigilimab (anti-TIGIT) and navicixizumab. Etigilimab is in a Phase 1b/2 trial for recurrent/advanced solid tumors, while navicixizumab has completed a Phase 1 study and is under a global licensing agreement with OncXerna Therapeutics Inc.
Financially, Mereo reported cash and short-term deposits of £51.2 million as of September 30, 2023, with a cash runway extending into 2026. The company has also recently entered into a global license agreement with ReproNovo SA for leflutrozole, a non-steroidal aromatase inhibitor.
Mereo BioPharma's commitment to rare disease therapeutics positions it as a significant player in the biopharmaceutical landscape, with ongoing advancements in its clinical programs and strategic partnerships shaping its path forward.
Mereo BioPharma (MREO) presented secondary endpoint data from the Phase 2b ASTEROID study for UX143 (setrusumab) at the ASBMR 2021 Annual Meeting. The study revealed a statistically significant bone-building effect in Osteogenesis Imperfecta (OI) patients, with an 8.97% increase in lumbar spine bone mineral density at 12 months in the highest dose cohort. Improvements in bone strength at the wrist and tibia were also observed. Following these results, Mereo BioPharma and Ultragenyx plan to advance UX143 into late-stage development for various OI subtypes.
Mereo BioPharma Group plc (NASDAQ: MREO) has appointed Pierre Jacquet, M.D., Ph.D. to its Board of Directors as of September 20, 2021. Dr. Jacquet brings over 20 years of experience in life sciences and strategy, previously serving as Managing Director at L.E.K. Consulting. His expertise is expected to enhance the company's clinical portfolio development. Concurrently, Peter Bains has retired from the Board after over six years of service. Mereo focuses on innovative therapies for oncology and rare diseases, with product candidates in various stages of clinical trials.
Mereo BioPharma Group plc (NASDAQ: MREO) announced participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference (Sept 13-14), SVB Leerink CybeRx Series (Sept 22-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 30 at 9:30am ET). A live audio webcast of the fireside chat at the Cantor Fitzgerald event will be available on the Company’s website. Mereo is focused on developing innovative therapeutics for oncology and rare diseases, with notable advances in clinical trials.
Infinity Pharmaceuticals announces the appointment of Robert Ilaria, Jr. as Chief Medical Officer, leading the clinical development of eganelisib, an oral immuno-oncology therapeutic. Ilaria brings extensive oncology experience, notably from his roles at Bristol Myers Squibb and Celgene. Brian Schwartz, previously Consulting Chief Physician, transitions to the Board of Directors. The press release highlights the promising data from ongoing studies, particularly in treating bladder and triple negative breast cancers, with plans for future development and registration studies.
Mereo BioPharma (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will speak at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 9:30 AM ET. A live audio webcast will be available on the Company’s website, with a replay accessible for two weeks.
Mereo focuses on developing therapeutics for oncology and rare diseases, with key products including etigilimab for various tumors and alvelestat for Alpha-1 antitrypsin deficiency. The Company aims to deliver improved health outcomes in these areas.
Mereo BioPharma (NASDAQ: MREO) announced positive interim data from a study of alvelestat for Bronchiolitis Obliterans Syndrome (BOS) post-hematopoietic stem cell transplantation. The Phase 1b/2 study, in collaboration with the National Cancer Institute, aims to recruit 30 patients. Initial results indicated that alvelestat was well tolerated, with six of seven patients showing stable disease. Significant reductions in the desmosine biomarker were observed, suggesting alvelestat's efficacy in inhibiting neutrophil elastase. Further analyses are planned for the upcoming ASH 2021 meeting.
Mereo BioPharma Group plc (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021, at 8:00 AM Eastern Time. Investors can access the live audio webcast on the company’s website, with an archived version available for two weeks post-event. Mereo focuses on developing innovative therapeutics for oncology and rare diseases, boasting a robust pipeline including etigilimab and navicixizumab for cancers, and alvelestat and setrusumab for rare diseases.
Mereo BioPharma Group plc (NASDAQ: MREO) will host a virtual R&D day on May 13, 2021, to discuss its etigilimab (Anti-TIGIT) program, focusing on studies for ovarian, cervical cancer, and sarcoma. The event features key opinion leaders and will include updates on the Phase 1b/2 ACTIVATE study and a collaboration with the Cancer Focus Fund for a clinical trial at MD Anderson Cancer Center. Mereo aims to enhance outcomes in oncology and rare diseases with its advanced product candidates.
Mereo BioPharma has announced a partnership with Cancer Focus Fund to evaluate its lead anti-TIGIT antibody, etigilimab, in a Phase 1b/2 clinical study for clear cell ovarian cancer, a rare form of the disease. The study, to be conducted at The University of Texas MD Anderson Cancer Center, will be financed with an upfront consideration of $1.5 million in Mereo shares, along with milestone payments. This collaboration marks the first investment by Cancer Focus Fund, aimed at advancing promising cancer therapies.
Mereo BioPharma Group (NASDAQ: MREO) will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 11:00am Eastern Time. Interested parties can access a live audio webcast via the company’s website, with an archived replay available for two weeks.
Mereo focuses on oncology and rare diseases, featuring six clinical-stage product candidates. Its lead candidate, etigilimab, is in Phase 1b/2 study, while navicixizumab targets late-line ovarian cancer. The company also investigates alvelestat for Alpha-1 antitrypsin deficiency and setrusumab for osteogenesis imperfecta.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
What is Mereo BioPharma Group plc?
What are the main products of Mereo BioPharma?
What is the focus of Mereo BioPharma's recent clinical trials?
Who are Mereo BioPharma's key partners?
How is Mereo BioPharma financially positioned?
What are the future plans for setrusumab?
What is the latest update on alvelestat?
What other areas is Mereo BioPharma involved in?
What are the milestone payments and royalties associated with Mereo's partnerships?
What is the significance of Mereo BioPharma's recent licensing agreement with ReproNovo SA?
